Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNγ Administration


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

We studied changes in the population of human multipotent mesenchymal stromal cells activated by IFNγ. The cells were cultured under standard conditions; IFNγ was added in various concentrations for 4 h or over 2 passages. It was shown that the total cell production significantly decreased after long-term culturing with IFNγ, but 4-h exposure did not affect this parameter. After 4-h culturing, the expression levels of IDO1, CSF1, and IL-6 increased by 300, 7, and 2.4 times, respectively, and this increase persisted 1 and 2 days after removal of IFNγ from the culture medium. The expression of class I and II MHC (HLA) on cell surface practically did not change immediately after exposure to IFNγ, but during further culturing, HLA-ABC (MHC I) and HLA-DR (MHC II) expression significantly increased, which abolished the immune privilege in these cells, the property allowing clinical use of allogenic multipotent mesenchymal stromal cells. Multipotent mesenchymal stromal cells can suppress proliferation of lymphocytes. The degree of this suppression depends on individual properties of multipotent mesenchymal stromal cell donor. Treatment with IFNγ did not significantly affect the intensity of inhibition of lymphocyte proliferation by these cells.

Авторлар туралы

N. Petinati

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

N. Kapranov

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

A. Bigil’deev

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

M. Popova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

Yu. Davydova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

I. Gal’tseva

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

N. Drize

Hematology Research Center, Ministry of Health Care of the Russian Federation

Хат алмасуға жауапты Автор.
Email: ndrize@yandex.ru
Ресей, Moscow

L. Kuz’mina

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

E. Parovichnikova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow

V. Savchenko

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Ресей, Moscow


© Springer Science+Business Media, LLC, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>